Fosamax Osteonecrosis of the Jaw Settlement Criteria Explained

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health Awareness to Specific Medication Risks

For decades, public health communication has centered on broad wellness principles and accessible medical knowledge, helping individuals make informed lifestyle choices. This legacy of general health and science information established a foundation for understanding how medications interact with the body over time. Within this context, the transition to more specialized health concerns requires careful attention to specific exposure pathways and their potential consequences. The shift from general health awareness to occupational exposure concern becomes particularly relevant when considering pharmaceutical agents that may affect bone metabolism. Bisphosphonates such as Fosamax, originally developed to address osteoporosis, have been associated with rare but serious conditions like osteonecrosis of the jaw. This condition, characterized by exposed bone in the maxillofacial region, has prompted legal settlements for affected individuals. Understanding the settlement criteria involves recognizing that exposure duration, dosage, and individual risk factors all play roles in determining eligibility. From a public health perspective, this evolution from general wellness information to targeted risk assessment reflects the growing complexity of medication management. The bridge between broad health literacy and specific exposure concerns lies in acknowledging that even widely prescribed treatments carry potential long-term implications that warrant careful monitoring and, when necessary, legal recourse for those harmed.

Understanding Fosamax and Osteonecrosis of the Jaw

Fosamax (alendronate) is a bisphosphonate medication prescribed for the treatment of osteoporosis. A known adverse effect associated with its use is osteonecrosis of the jaw (ONJ), a condition characterized by exposed bone in the maxillofacial region that fails to heal. Understanding the clinical presentation, risk factors, and settlement criteria for affected patients requires a careful review of the available evidence. Osteonecrosis of the jaw can occur spontaneously, but it is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The condition has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting dentures) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The time to onset of symptoms varied from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients had relief of symptoms after stopping the medication, but a subset had recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Mechanistic Pathways and Research Findings

Mechanistic pathways linking Fosamax to ONJ are still under investigation. A multiscale characterization of jawbone in estrogen-deficient rats treated with bisphosphonate (alendronate) showed that most jawbone characteristics in ovariectomized (OVX) and treatment groups were not significantly different from those of the sham group (https://pubmed.ncbi.nlm.nih.gov/40345077/). The surface of alveolar bone surrounding teeth showed a trend of more erosion and addition of new bone tissues in the OVX rat groups compared to the sham group (https://pubmed.ncbi.nlm.nih.gov/40345077/). All tissue mineral density parameters rapidly increased up to 60 μm from the periodontal ligament surrounding teeth regardless of the treatment groups (https://pubmed.ncbi.nlm.nih.gov/40345077/). Treatments using each therapeutic agent and its combination did not substantially change those characteristics of jawbones in OVX rats (https://pubmed.ncbi.nlm.nih.gov/40345077/). These findings are different from those of lumbar vertebrae in the same rats that showed a significant bone alteration by OVX and treatments (https://pubmed.ncbi.nlm.nih.gov/40345077/). This research provides comprehensive information that can help better understand jawbone-specific responses to bone-related complications, including bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077/).

Settlement Criteria and Legal Considerations

Settlement-related considerations for affected patients hinge on several factors. The adequacy of warnings regarding Fosamax and ONJ is a central issue. The FDA-approved labeling for Fosamax includes a warning about ONJ, noting that it can occur spontaneously and is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The labeling also lists known risk factors and advises that discontinuation of bisphosphonate treatment may reduce the risk for ONJ in patients requiring invasive dental procedures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). However, the timeline between exposure and documented harm can vary widely, from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This variability complicates the establishment of a clear causal link in individual cases. For patients considering legal action, settlement criteria typically require evidence of a diagnosis of ONJ, documented use of Fosamax, and a temporal relationship between the drug exposure and the onset of symptoms. The presence of known risk factors, such as invasive dental procedures or concomitant therapies, may also be considered. It is important to note that in placebo-controlled clinical studies, the percentages of patients with symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56), which may affect the assessment of causation. Patients should consult with legal and medical professionals to evaluate their individual circumstances.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is Fosamax and how is it linked to osteonecrosis of the jaw?

Fosamax (alendronate) is a bisphosphonate used to treat osteoporosis. It has been associated with osteonecrosis of the jaw (ONJ), a condition where jawbone becomes exposed and fails to heal. ONJ can occur spontaneously or after dental procedures, and the risk may increase with longer use (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

What are the settlement criteria for Fosamax-related ONJ claims?

Settlement criteria typically require a confirmed diagnosis of ONJ, documented use of Fosamax, and a temporal relationship between drug exposure and symptom onset. Risk factors like dental procedures or concomitant therapies may also be considered. Legal and medical consultation is advised to evaluate individual cases.

Where can I find authoritative information on Fosamax and ONJ?

Authoritative sources include the FDA-approved labeling on DailyMed (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56) and research articles on PubMed (https://pubmed.ncbi.nlm.nih.gov/40345077/). These provide detailed risk factors, clinical data, and safety information.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.